W. Michael  Flanagan net worth and biography

W. Flanagan Biography and Net Worth

W. Michael Flanagan, Chief Scientific and Technical Officer, joined Avidity Biosciences in January 2021. Dr. Flanagan has extensive experience developing multiple therapeutic modalities, including RNA therapeutics, antibody drug conjugates, and bispecific antibodies. Prior to joining Avidity, Dr. Flanagan served as Senior Director and Project Team Leader, Oncology and Immunology for Genentech, Inc., where he advanced programs through late-stage research to end of Phase 2 development. Prior to Genentech, he served in roles of increasing responsibility in the biology groups at Sunesis Pharmaceuticals, Inc., Gilead Sciences, Inc., and Merck & Co., Inc. where he was Senior Director of RNA Sciences. Dr. Flanagan received a B.S. in Genetics from the University of California at Davis, a Ph.D. in Biological Sciences from the University of California at Irvine and was an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute, Stanford University.

How old is W. Michael Flanagan?

Dr. Flanagan is currently 61 years old. There are 7 older executives and no younger executives at Avidity Biosciences. The oldest executive at Avidity Biosciences is Dr. Frank P. McCormick Ph.D., Scientific Founder & Member of Scientific Advisory Board, who is 74 years old. Learn More on W. Michael Flanagan's age.

How do I contact W. Michael Flanagan?

The corporate mailing address for Dr. Flanagan and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at [email protected]. Learn More on W. Michael Flanagan's contact information.

Has W. Michael Flanagan been buying or selling shares of Avidity Biosciences?

W. Michael Flanagan has not been actively trading shares of Avidity Biosciences in the last ninety days. Learn More on W. Michael Flanagan's trading history.

Who are Avidity Biosciences' active insiders?

Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), Teresa Mccarthy (Insider), and Tamar Thompson (Director). Learn More on Avidity Biosciences' active insiders.

Are insiders buying or selling shares of Avidity Biosciences?

During the last year, insiders at the biotechnology company sold shares 31 times. They sold a total of 883,681 shares worth more than $29,962,658.51. The most recent insider tranaction occured on November, 19th when Director Arthur A Levin sold 3,323 shares worth more than $139,964.76. Insiders at Avidity Biosciences own 3.7% of the company. Learn More about insider trades at Avidity Biosciences.

Information on this page was last updated on 11/19/2024.

W. Michael Flanagan Insider Trading History at Avidity Biosciences

See Full Table

W. Michael Flanagan Buying and Selling Activity at Avidity Biosciences

This chart shows W. Michael Flanagan's buying and selling at Avidity Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Avidity Biosciences Company Overview

Avidity Biosciences logo
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $40.06
Low: $39.86
High: $41.46

50 Day Range

MA: $45.44
Low: $41.35
High: $52.50

2 Week Range

Now: $40.06
Low: $6.79
High: $56.00

Volume

360,073 shs

Average Volume

1,299,524 shs

Market Capitalization

$4.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89